Pharmacological modulation of NLRP3 inflammasomes has been explored in preclinical models of diseases such as atherosclerosis (126), gout (127), and inflammatory bowel disease (128), providing promising evidence of the potential of NLRP3 inhibitors in the treatment of inflammatory diseases. This evidence concerns the gene NLRP3 and gout.